These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18667648)

  • 21. Rationing in the fiscal ice age.
    Klein R
    Health Econ Policy Law; 2010 Oct; 5(4):389-96. PubMed ID: 20565993
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence-informed evidence-making.
    Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
    J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accountability for rationing--theory into practice.
    Newdick C
    J Law Med Ethics; 2005; 33(4):660-8. PubMed ID: 16686237
    [No Abstract]   [Full Text] [Related]  

  • 25. NICE quality standards: improving healthcare quality in the English NHS?
    Stokes T
    Qual Prim Care; 2013; 21(4):207-9. PubMed ID: 24041137
    [No Abstract]   [Full Text] [Related]  

  • 26. Challenges for the National Institute for Clinical Excellence.
    Maynard A; Bloor K; Freemantle N
    BMJ; 2004 Jul; 329(7459):227-9. PubMed ID: 15271837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scandal as a Sentinel Event--Recognizing Hidden Cost-Quality Trade-offs.
    Bloche MG
    N Engl J Med; 2016 Mar; 374(11):1001-3. PubMed ID: 26981930
    [No Abstract]   [Full Text] [Related]  

  • 28. Rationing healthcare: the appeal of muddling through elegantly.
    Hunter DJ
    Healthc Pap; 2001; 2(2):31-7; discussion 69-75. PubMed ID: 12811143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How NICE may be outflanked.
    Ferner RE; McDowell SE
    BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
    [No Abstract]   [Full Text] [Related]  

  • 30. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
    Gafni A; Birch S; ;
    Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis without treatment as a modifier in health economic assessments.
    Camidge R; Walker A; Oliver JJ; Nussey F; Maxwell S; Jodrell D; Webb DJ
    BMJ; 2005 Jun; 330(7504):1382-4. PubMed ID: 15947403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do NICE and CHI have no interest in safety? Opinion of the book NICE, CHI and the NHS reforms. Enabling excellence or imposing control?
    Fletcher P
    Adverse Drug React Toxicol Rev; 2000 Aug; 19(3):167-76. PubMed ID: 11059357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. It is the lifetime that matters: public preferences over maximising health and reducing inequalities in health.
    Dolan P; Tsuchiya A
    J Med Ethics; 2012 Sep; 38(9):571-3. PubMed ID: 22493185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving the contribution of public health to NHS decision making: development of an instrument.
    Leach J; McKeown K
    Public Health; 1998 Nov; 112(6):393-8. PubMed ID: 9883036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using PBMA in health care priority setting: description, challenges and experience.
    Mitton C; Peacock S; Donaldson C; Bate A
    Appl Health Econ Health Policy; 2003; 2(3):121-7. PubMed ID: 14984275
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness considerations at NICE.
    Rawlins M; Dillon A
    Lancet; 2008 Oct; 372(9646):1302. PubMed ID: 18929903
    [No Abstract]   [Full Text] [Related]  

  • 38. From rationing to rational: the evolving status of NICE.
    Minhas R; Patel KC
    J R Soc Med; 2008 Sep; 101(9):436-42. PubMed ID: 18779244
    [No Abstract]   [Full Text] [Related]  

  • 39. Can NICE guidance be given more clout?
    Mayor S
    BMJ; 2006 Jul; 333(7560):170. PubMed ID: 16858045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Living in a state of denial. Is the NHS right to deny drugs for cancer before it is terminal?
    Jeffs L; Lehane M; Justice S; Singleton C
    Nurs Stand; 2005 Jul 20-26; 19(45):28-9. PubMed ID: 16050225
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.